Consensus Fulgent Genetics, Inc.

Stocks

FLGT

US3596641098

Healthcare Facilities & Services

Market Closed - Nasdaq 23:00:00 30/10/2026 +03			5-day change	1st Jan Change
20.62 ^USD	-4.89%		+2.59%	-21.51%

07-31	Fulgent Genetics, Inc., Q2 2026 Earnings Call, Jul 30, 2026
07-30	Tranche Update on Fulgent Genetics, Inc.'s Equity Buyback Plan announced on March 8, 2022.	CI

Evolution of the Average Target: Fulgent Genetics, Inc.

Evolution of the Target Price: Fulgent Genetics, Inc.

Changes in Analyst Recommendations: Fulgent Genetics, Inc.

4a632ec7d199cb03ce32a676f2cf.uxTy1iv96dYtGajI07eqobDo4DkIXAjcaYjpsCJPAb0.gkWgrhqZhI4dSMmEt_zo2dGBg1huCWW0E-C_hkUZZtfZf8qjU4uDo0JdmA~156e1f35aa08455d70655c2d749dd8eb

Analysts' recommendations: Fulgent Genetics, Inc.

03-02	UBS Adjusts Fulgent Genetics Price Target to $22 From $35, Maintains Buy Rating	MT
05/08/25	UBS Upgrades Fulgent Genetics to Buy From Neutral, Adjusts Price Target to $30 From $20	MT
01/08/25	Fulgent Genetics beats Q2 revenue estimates	RE
03/03/25	UBS Adjusts Fulgent Genetics Price Target to $20 From $27, Maintains Neutral Rating	MT
05/08/24	UBS Adjusts Fulgent Genetics Price Target to $27 From $25, Maintains Neutral Rating	MT
06/03/24	Piper Sandler Adjusts Price Target on Fulgent Genetics to $25 From $28, Maintains Neutral Rating	MT
29/02/24	UBS Adjusts Fulgent Genetics Price Target to $25 From $35, Maintains Neutral Rating	MT
07/12/23	UBS Initiates Coverage on Fulgent Genetics With Neutral Rating, $35 Price Target	MT
02/03/23	Credit Suisse Lowers Fulgent Genetics' Price Target to $45 From $50 After Mixed Q4 Results, Keeps Outperform Rating	MT
08/12/22	Piper Sandler Downgrades Fulgent Genetics to Neutral From Overweight, Adjusts Price Target to $40 From $65	MT
18/11/22	Raymond James Starts Fulgent Genetics at Outperform With $45 Price Target	MT
14/11/22	Piper Sandler Adjusts Price Target on Fulgent Genetics to $65 From $70, Maintains Overweight Rating	MT
14/11/22	Credit Suisse Adjusts Fulgent Genetics' Price Target to $50 From $65, Keeps Outperform Rating	MT
25/08/22	Credit Suisse Initiates Fulgent Genetics at Outperform with $65 Price Target	MT
16/05/22	Piper Sandler Adjusts Fulgent Genetics' Price Target to $70 From $85, Reiterates Overweight Rating	MT
04/05/22	Oppenheimer Adjusts Fulgent Genetics Price Target to $112 From $123, Maintains Outperform Rating	MT
01/03/22	Piper Sandler Adjusts Fulgent Genetics' Price Target to $85 From $80, Reiterates Overweight Rating	MT
24/02/22	Oppenheimer Adjusts Fulgent Genetics Price Target to $123 From $125, Maintains Outperform Rating	MT
04/02/22	Piper Sandler Assumes Fulgent Genetics at Overweight with $80 Price Target	MT
25/01/22	Oppenheimer Adjusts Fulgent Genetics' Price Target to $125 From $141, Maintains Outperform Rating	MT
10/08/21	Fulgent Genetics : Credit Suisse Adjusts Fulgent Genetics' Price Target to $65 from $55, Keeps Underperform Rating	MT
10/08/21	Fulgent Genetics : Oppenheimer Adjusts Fulgent Genetics PT to $141 From $118, Maintains Outperform Rating	MT
07/05/21	Fulgent Genetics : Oppenheimer Adjusts Fulgent Genetics PT to $118 From $126, Maintains Outperform Rating	MT
07/04/21	Fulgent Genetics : Oppenheimer Adjusts Fulgent Genetics PT to $126 From $130 on Q1 Preview, Maintains Outperform Rating	MT
05/03/21	Fulgent Genetics : Piper Sandler Adjusts Price Target on Fulgent Genetics to $140 From $135, Maintains Overweight Rating	MT

More recommendations

Medical & Diagnostic Laboratories

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
FULGENT GENETICS, INC.	-	-	-	-7.86%
CVS HEALTH CORPORATION				+27.96%
HCA HEALTHCARE, INC.				-0.59%
NATERA, INC.				+0.5%
FRESENIUS SE & CO. KGAA				+18.02%
LABCORP HOLDINGS INC.				+5.77%
QUEST DIAGNOSTICS INCORPORATED				+2.16%
TENET HEALTHCARE CORPORATION				+7.91%
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY				+19.93%
IHH HEALTHCARE				+31.59%
Average				+10.54%
Weighted average by Cap.				+12.08%